PMID- 17041628
OWN - NLM
STAT- MEDLINE
DCOM- 20061114
LR  - 20240109
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 25
IP  - 48
DP  - 2006 Oct 16
TI  - mTOR and cancer therapy.
PG  - 6436-46
AB  - Proteins regulating the mammalian target of rapamycin (mTOR), as well as some of 
      the targets of the mTOR kinase, are overexpressed or mutated in cancer. 
      Rapamycin, the naturally occurring inhibitor of mTOR, along with a number of 
      recently developed rapamycin analogs (rapalogs) consisting of synthetically 
      derived compounds containing minor chemical modifications to the parent 
      structure, inhibit the growth of cell lines derived from multiple tumor types in 
      vitro, and tumor models in vivo. Results from clinical trials indicate that the 
      rapalogs may be useful for the treatment of subsets of certain types of cancer. 
      The sporadic responses from the initial clinical trials, based on the hypothesis 
      of general translation inhibition of cancer cells are now beginning to be 
      understood owing to a more complete understanding of the dynamics of mTOR 
      regulation and the function of mTOR in the tumor microenvironment. This review 
      will summarize the preclinical and clinical data and recent discoveries of the 
      function of mTOR in cancer and growth regulation.
FAU - Easton, J B
AU  - Easton JB
AD  - Department of Molecular Pharmacology, St Jude Children's Research Hospital, 
      Memphis, TN 38105, USA.
FAU - Houghton, P J
AU  - Houghton PJ
LA  - eng
GR  - CA21765/CA/NCI NIH HHS/United States
GR  - CA23099/CA/NCI NIH HHS/United States
GR  - CA77776/CA/NCI NIH HHS/United States
GR  - CA96966/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (Antibiotics, Antineoplastic)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - Autophagy
MH  - Cell Hypoxia
MH  - Enzyme Activation
MH  - Humans
MH  - Neoplasms/*drug therapy/enzymology/pathology/physiopathology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Kinases/*physiology
MH  - Sirolimus/therapeutic use
MH  - Stem Cells/physiology
MH  - TOR Serine-Threonine Kinases
RF  - 83
EDAT- 2006/10/17 09:00
MHDA- 2006/11/15 09:00
CRDT- 2006/10/17 09:00
PHST- 2006/10/17 09:00 [pubmed]
PHST- 2006/11/15 09:00 [medline]
PHST- 2006/10/17 09:00 [entrez]
AID - 1209886 [pii]
AID - 10.1038/sj.onc.1209886 [doi]
PST - ppublish
SO  - Oncogene. 2006 Oct 16;25(48):6436-46. doi: 10.1038/sj.onc.1209886.